The corporate team at Spearing Waite has advised venture capital provider Longwall Venture Partners on its investment in Oxford HighQ.
The investment, led by Longwall Partner David Denny, will support the company’s current work to develop analytical instruments for chemical, biological and materials sciences using nanophotonic tools.
Oxfordshire-based Longwall Venture Partners invests in innovative, UK-based, early stage companies in the healthcare, science and engineering sectors.
Spearing Waite has acted for Longwall since 2010 and advised the firm on their £75 million venture capital fundraise, known as Longwall Ventures 3 ECF, last year.
This is the second investment Spearing Waite has advised on from that fund, having previously advised on the investment in Closed Loop Medicine. Closed Loop Medicine use the concept of convergence to create new closed-loop models of care and integrates real-time feedback to optimise outcomes for patients.
David Denny, Partner at Longwall, commented:
“We are incredibly excited about the market opportunities for the next generation chemical and nanoparticle sensors being developed by the talented team at Oxford HighQ. Having worked closely with them over a number of months, it is clear that their work will lead to a real step change in the industry and we are delighted to support them as they enter this key phase of their growth and development.”
Jahid Ali, Head of Corporate at Spearing Waite, said:
“We are delighted to be working with Longwall on this venture capital investment, which required highly specialist legal expertise.
“Our relationship with Longwall has gone from strength to strength and we are so pleased to be part of another promising investment in a company at the forefront of science and technology.”
The deal follows Spearing Waite’s success in winning the Highly Commended accolade at the annual East Midlands Dealmakers Awards 2018 as well as their record results for 2017 where they advised on around £300 million worth of transactions.